Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 03, 2023

Zanubrutinib vs Ibrutinib for Symptomatic Waldenström Macroglobulinemia

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
J. Clin. Oncol 2023 Jul 21;[EPub Ahead of Print], MA Dimopoulos, S Opat, S D'Sa, W Jurczak, HP Lee, G Cull, RG Owen, P Marlton, BE Wahlin, R Garcia-Sanz, H McCarthy, S Mulligan, A Tedeschi, JJ Castillo, J Czyz, C Fernández de Larrea, D Belada, E Libby, J Matous, M Motta, T Siddiqi, M Tani, M Trněný, MC Minnema, C Buske, V Leblond, SP Treon, J Trotman, WY Chan, J Schneider, H Allewelt, S Patel, A Cohen, CS Tam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading